<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Treatment and prevention of West Nile virus infection
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Treatment and prevention of West Nile virus infection
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Treatment and prevention of West Nile virus infection
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lyle R Petersen, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Martin S Hirsch, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer Mitty, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jul 15, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         West Nile (WN) virus, a member of the Japanese encephalitis virus antigenic complex, can lead to a wide range of clinical symptoms from asymptomatic disease to severe meningitis and encephalitis.
        </p>
        <p>
         Management and prevention of WN virus are discussed below. The clinical manifestations and epidemiology of the infection are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1304.html" rel="external">
          "Epidemiology and pathogenesis of West Nile virus infection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1273.html" rel="external">
          "Clinical manifestations and diagnosis of West Nile virus infection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Supportive care remains the mainstay of treatment for WN virus infection. (See
         <a class="local">
          'Supportive care'
         </a>
         below.)
        </p>
        <p>
         The potential use of several different therapeutic agents has also been described [
         <a href="#rid1">
          1-11
         </a>
         ]. However, there are no data to support the routine use of any agents, and uncontrolled studies or case reports suggesting treatment efficacy should be cautiously interpreted, since the clinical course and outcomes with WN virus neuroinvasive disease are highly variable [
         <a href="#rid1">
          1,2
         </a>
         ]. (See
         <a class="local">
          'Agents with potential benefit'
         </a>
         below and
         <a class="local">
          'Agents without benefit'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3874549235">
         <span class="h2">
          Supportive care
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of WN virus infection is primarily supportive.
        </p>
        <p>
         Supportive therapy may include pain control for headaches; if nausea and vomiting are present, antiemetic therapy and rehydration may be beneficial. (See
         <a class="medical medical_review" href="/z/d/html/2538.html" rel="external">
          "Characteristics of antiemetic drugs"
         </a>
         .)
        </p>
        <p>
         Patients with encephalitis should be monitored for signs and symptoms of elevated intracranial pressure and seizures. (See
         <a class="medical medical_review" href="/z/d/html/1659.html" rel="external">
          "Evaluation and management of elevated intracranial pressure in adults", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
         In some patients, particularly those with poliomyelitis-like symptoms, airway protection and ventilatory support may be needed. (See
         <a class="medical medical_review" href="/z/d/html/268.html" rel="external">
          "The decision to intubate"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4166030848">
         <span class="h2">
          Agents with potential benefit
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with WN fever, there is no clear role for treatments other than supportive care. (See
         <a class="local">
          'Supportive care'
         </a>
         above.)
        </p>
        <p>
         There are certain agents that may be of potential benefit for treatment of patients with WN virus neuroinvasive disease; however, data are conflicting, and the risks and benefits of using one of these agents must be determined on a case-by-case basis. These agents include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Corticosteroids
         </strong>
         – The rationale for corticosteroid therapy in the setting of WN virus is to inhibit proinflammatory mediators that may contribute to the pathogenesis of WN virus in the central nervous system. Several individual case reports have described clinical improvement after administration of high-dose corticosteroids for a variety of neurological complications of WN virus infection (eg, acute flaccid paralysis, opsoclonus myoclonus ataxia) [
         <a href="#rid12">
          12-15
         </a>
         ]. However, in a nonrandomized series of patients with neuroinvasive disease, no difference was noted in the duration of hospitalization for the 18 patients treated with
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         or other steroids compared with untreated patients [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intravenous immunoglobulin
         </strong>
         – There is a theoretical benefit of administering intravenous immunoglobulin (
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         ) in patients with WN virus neuroinvasive disease who have humoral deficiencies. In the United States and Europe, high titer neutralizing antibodies have been demonstrated in plasma as a consequence of recurring WN virus outbreaks [
         <a href="#rid9">
          9,17
         </a>
         ], and animal studies suggested there may be a potential role for the use of IVIG for the prevention and treatment of WN virus infection [
         <a href="#rid9">
          9,10,18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However,
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         has been administered to immunocompromised patients with varied outcomes [
         <a href="#rid11">
          11,19-21
         </a>
         ]. In, a randomized, placebo-controlled safety trial in 62 patients with neuroinvasive disease (the majority who were immunocompetent) failed to find benefit of a high-titered IVIG derived from Israeli donors, although this trial was designed to determine safety and not efficacy [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Limited data have also suggested a potential benefit of interferon alfa therapy, but interferon should
         <strong>
          not
         </strong>
         be used for treatment of WN virus infection given the toxicity associated with interferon and the limited data supporting its use. Alfa interferon was found to be effective against WN virus in in vitro and in animal models [
         <a href="#rid3">
          3-5
         </a>
         ]. In addition, rapid neurologic improvement was demonstrated in two patients with serologically confirmed WN virus infection who presented with deteriorating mental status and progression to coma and were treated with standard
         <a class="drug drug_general" data-topicid="8563" href="/z/d/drug information/8563.html" rel="external">
          interferon alfa-2b
         </a>
         within 72 hours of presentation [
         <a href="#rid6">
          6
         </a>
         ]. However, it remains unclear if the change in clinical status in these patients was due to interferon or to spontaneous improvement, which has been documented in untreated WN virus infection [
         <a href="#rid1">
          1
         </a>
         ]. In addition, another report described two patients who developed WN fever after mosquito exposure while receiving interferon alfa-2b and
         <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">
          ribavirin
         </a>
         for hepatitis C infection [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1269273704">
         <span class="h2">
          Agents without benefit
         </span>
         <span class="headingEndMark">
          —
         </span>
         There does not appear to be a role for treatment of WN virus disease with the following agents given lack of efficacy:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">
          Ribavirin
         </a>
         – The antiviral agent ribavirin has demonstrated in vitro activity against WN virus, but therapeutic efficacy has not been demonstrated. Ribavirin increased mortality in Syrian golden hamsters when administered two days after inoculation [
         <a href="#rid3">
          3
         </a>
         ]. In addition, during an outbreak in Israel, ribavirin appeared to be ineffective and possibly detrimental when it was used in an uncontrolled, nonblinded fashion in some patients with WN virus neuroinvasive disease [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          Acyclovir
         </a>
         – There does not appear to be a role for acyclovir in the treatment of WN virus infection based upon data from retrospective case series [
         <a href="#rid16">
          16,22
         </a>
         ]. In one report that included 49 patients treated with acyclovir, the duration of hospitalization did not differ compared with untreated patients [
         <a href="#rid16">
          16
         </a>
         ]. In another series of 165 patients with neuroinvasive disease, 94 patients were treated with acyclovir for a median of eight days, and there was no clinical benefit compared with untreated patients [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Serious adverse outcomes from WN virus infection are limited to the patients who develop neuroinvasive disease [
         <a href="#rid23">
          23
         </a>
         ]. Older age is the most important predictor of risk [
         <a href="#rid23">
          23-25
         </a>
         ]. Increased severity of neuroinvasive disease may also be seen in immunocompromised patients, such as solid organ transplant recipients [
         <a href="#rid26">
          26,27
         </a>
         ].
        </p>
        <p>
         In a review of 6744 patients with neuroinvasive disease in the United States from 2009 to 2018, the case fatality rate was 2 percent in patients with meningitis, 14 percent in patients with encephalitis, and 13 percent in those with acute flaccid paralysis [
         <a href="#rid28">
          28
         </a>
         ]. The median age of patients with encephalitis was higher than that in patients with acute flaccid paralysis or meningitis (66, 60, and 52 years, respectively). Mortality was associated with advanced age (2 percent among patients &lt;50 years comparted to 21 percent of those aged &gt;70 years). A multinational study indicated that age and the presence of coma were independent predictors of fatal outcome [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
         Conflicting data have been published on the long-term prognosis of patients with neuroinvasive WN virus infection [
         <a href="#rid1">
          1,29,30
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One study evaluated self-perceived health outcomes among 40 New York City residents who developed meningitis or encephalitis during the 1999 WN virus epidemic and survived [
         <a href="#rid29">
          29
         </a>
         ]. At 12 months, only 37 percent achieved a full recovery, which was most likely to occur in patients less than 65 years of age. Long-term neurologic sequelae included muscle weakness, loss of concentration, confusion, and light-headedness.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another retrospective study evaluated 49 patients with laboratory-confirmed WN virus infection approximately one year after clinical presentation, including 38 patients who did not have neuroinvasive disease [
         <a href="#rid31">
          31
         </a>
         ]. The most frequent somatic complaints (present in at least one-third of patients) were fatigue, memory problems, extremity symptoms (weakness, numbness or tingling, pain or myalgia), word-finding difficulty, and headaches. Standardized testing revealed moderate to severe depression in 24 percent. Physical examination documented tremor in six patients. Neuropsychological tests of motor function indicated that 69 percent of patients scored &gt;2 standard deviations below the norm.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a longitudinal cohort study of 156 persons with WN virus infection (41 percent of whom had neuroinvasive disease), physical and cognitive function returned to normal in approximately one year [
         <a href="#rid32">
          32
         </a>
         ]. The estimated times until 95 percent recovery of physical function was restored were significantly different in participants with neuroinvasive disease than in those without (175 days versus 121 days, respectively); however, time to recovery of mental function was similar between both patient groups. Lack of comorbid illness at baseline was associated with a faster rate of overall recovery.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A longitudinal cohort study followed 103 persons with WN virus infection (62 percent had neuroinvasive disease) for up to eight years [
         <a href="#rid33">
          33
         </a>
         ]. Many patients still reported symptoms one and eight years after infection (60 and 40 percent, respectively), possibly related to WN disease. Such symptoms included fatigue, weakness, and depression. Older patients and those with neuroinvasive disease were more likely to report continued symptoms.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Health related quality of life was measured in 154 patients with WN virus infection who were followed for up to three years [
         <a href="#rid34">
          34
         </a>
         ]. At baseline, quality of life scores (measured using the Medical Outcomes Survey Short Form 36) were much lower for those with neuroinvasive disease compared to those without neuroinvasive disease. This gap nearly closed after six months; however, after three years scores remained lower than population norms in both groups.
        </p>
        <p>
        </p>
        <p>
         The long-term functional outcome of patients with WN virus poliomyelitis is variable. Most patients have incomplete recovery of limb strength resulting in profound residual deficits [
         <a href="#rid1">
          1,26,35-37
         </a>
         ]. At one year follow-up, 18 of 27 patients with WN virus poliomyelitis had strength improvement, with improvement greatest during the first four months [
         <a href="#rid37">
          37
         </a>
         ]. Quadriplegia and respiratory failure are associated with high morbidity and mortality, and recovery is slow and typically incomplete [
         <a href="#rid37">
          37,38
         </a>
         ]. A smaller study has suggested that estimation of surviving motor unit numbers by motor unit number estimation (MUNE) may predict functional outcome [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          PREVENTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prevention of infection includes personal protection measures, mosquito control programs, and blood donor screening. Surveillance programs that can detect an increase in arboviral activity are important so that prevention efforts (eg, personal protection, mosquito control) can be implemented and/or enhanced [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Personal protection measures
         </span>
         <span class="headingEndMark">
          —
         </span>
         Personal protection measures to avoid mosquito exposure are a mainstay of prevention [
         <a href="#rid41">
          41
         </a>
         ]. A variety of insect repellants are available. (See
         <a class="medical medical_review" href="/z/d/html/4085.html" rel="external">
          "Prevention of arthropod and insect bites: Repellents and other measures"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Mosquito control
         </span>
         <span class="headingEndMark">
          —
         </span>
         It is important to drain standing water where mosquitoes are likely to breed. In a case control study examining risk factors, only spending increased amounts of time outdoors and the presence of flooded basements correlated with infection [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
         Organized community mosquito control programs that employ integrated pest management techniques can also reduce the risk of WN virus infection [
         <a href="#rid43">
          43
         </a>
         ]. Elimination of mosquito breeding sites and application of larvicides reduce the production of adult mosquitoes. When human or mosquito surveillance indicates heightened human infection risk, measures to reduce adult mosquitoes are undertaken, usually by truck-mounted or aerial insecticide spraying. These measures may considerably reduce subsequent human infection WN virus risk [
         <a href="#rid44">
          44-46
         </a>
         ] with negligible pesticide exposure [
         <a href="#rid47">
          47,48
         </a>
         ] and associated insecticide-related illness [
         <a href="#rid49">
          49,50
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Blood donor screening programs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Blood donor screening for WN virus has greatly reduced, but not eliminated, the risk of transfusion transmission [
         <a href="#rid51">
          51
         </a>
         ]. WN virus infection should be considered in recent transfusion recipients with unexplained, compatible illness. (See
         <a class="medical medical_review" href="/z/d/html/7946.html" rel="external">
          "Blood donor screening: Laboratory testing", section on 'West Nile virus'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Vaccine development
         </span>
         <span class="headingEndMark">
          —
         </span>
         There has been great interest in a WN virus vaccine; however, there are no human vaccines for prevention of WN virus.
        </p>
        <p>
         Four equine WN virus vaccines are licensed in the United States [
         <a href="#rid52">
          52
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Three inactivated virus vaccines.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A recombinant canarypox virus vaccine expressing the prM/E proteins of a 1999 WN virus isolate.
        </p>
        <p>
        </p>
        <p>
         Two other vaccines have been marketed but are no longer available. One was a plasmid DNA vaccine encoding for prM/E proteins. The other was a live, attenuated recombinant vaccine constructed from an infectious clone of yellow fever 17D virus, in which two genes have been replaced by two similar genes of WN virus. This vaccine was recalled because of adverse events.
        </p>
        <p>
         There are some encouraging preliminary data regarding potential candidate vaccines for humans:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Four human candidate vaccines have undergone phase I clinical trials. These include a vaccine that utilized plasmid DNA expressing West Nile virus prM/E genes [
         <a href="#rid53">
          53,54
         </a>
         ]; a recombinant E protein vaccine [
         <a href="#rid55">
          55
         </a>
         ]; a chimeric live, attenuated vaccine that combined the West Nile virus prM/E with the DENV-4 nonstructural genes incorporating a 30-nucleotide deletion in the 3′UTR [
         <a href="#rid56">
          56,57
         </a>
         ]; and a hydrogen peroxide-inactivated vaccine [
         <a href="#rid58">
          58
         </a>
         ]. The first three of these vaccines produced seroconversion rates &gt;95 percent and good neutralizing antibody titers while the hydrogen peroxide-inactivated vaccine only achieved a seroconversion rate of 31 percent. All these vaccines were well tolerated.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A formalin-inactivated vaccine underwent phase I/II trials simultaneously [
         <a href="#rid59">
          59
         </a>
         ]. Limited data are available describing this trial and the vaccine's immunogenicity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a phase II study, 45 healthy adults were inoculated with ChimeriVax-WN02, a live, attenuated recombinant yellow fever 17D virus-based vaccine [
         <a href="#rid60">
          60
         </a>
         ]. All subjects developed neutralizing antibodies after a single injection, and the vaccine was well tolerated. The vast majority of subjects also developed specific CD4+ proliferative and CD8+ cytotoxic T-cell responses to WN virus antigens. A larger phase II trial subsequently found this chimeric vaccine safe and immunogenic in adults, including individuals who were &gt;65 years of age [
         <a href="#rid61">
          61,62
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          SPECIAL CONSIDERATIONS DURING PREGNANCY
         </span>
         <span class="headingEndMark">
          —
         </span>
         A causal relationship between WN virus and fetal abnormalities has not been proven. (See
         <a class="medical medical_review" href="/z/d/html/1273.html" rel="external">
          "Clinical manifestations and diagnosis of West Nile virus infection"
         </a>
         .)
        </p>
        <p>
         The Centers for Disease Control and Prevention (CDC) has made the following recommendations for prevention of WN virus and for management of women who are infected during pregnancy [
         <a href="#rid63">
          63,64
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pregnant women should take precautions to protect themselves from bites from potentially infected mosquitoes (eg, avoid being outdoors at dawn and dusk, wear protective clothing, use insect repellants containing DEET). (See
         <a class="medical medical_review" href="/z/d/html/4088.html" rel="external">
          "Insect and other arthropod bites"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pregnant women with meningitis, encephalitis, acute flaccid paralysis, or unexplained fever in an area of ongoing WN virus transmission should have serum tested for antibody to WN virus. If laboratory tests indicate recent infection with WN virus, the infection should be reported to the local or state health department, and the woman should be followed to determine the outcome of her pregnancy. (See
         <a class="medical medical_review" href="/z/d/html/1273.html" rel="external">
          "Clinical manifestations and diagnosis of West Nile virus infection", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If WN virus infection is diagnosed in pregnancy, care is supportive. An ultrasound examination of the fetus to screen for abnormalities should be considered no sooner than two to four weeks after onset of symptoms.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Amniotic fluid, chorionic villi, or fetal serum can be tested for evidence of WN virus infection. However, the sensitivity, specificity, and predictive value of these tests to evaluate fetal WN virus infection are not known, and the clinical consequences of fetal infection have not been determined. In cases of spontaneous or induced abortion, testing of all products of conception for evidence of WN virus infection is advised to document the effects of WN virus infection on pregnancy outcome.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Screening asymptomatic women for WN virus infection is
         <strong>
          not
         </strong>
         recommended because there is no treatment and the consequences of infection during pregnancy have not been well-defined.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clinical evaluation is recommended for infants born to mothers known or suspected to have WN virus infection during pregnancy (
         <a class="graphic graphic_table graphicRef81650" href="/z/d/graphic/81650.html" rel="external">
          table 1
         </a>
         ). Further evaluation should be considered if any clinical abnormality is identified or if laboratory testing indicates that an infant might have congenital WN virus infection (
         <a class="graphic graphic_table graphicRef58635" href="/z/d/graphic/58635.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2872329446">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/109959.html" rel="external">
          "Society guideline links: Infectious encephalitis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/4001.html" rel="external">
          "Patient education: West Nile virus infection (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         – The treatment of West Nile (WN) virus infection is primarily supportive. The use of several different therapeutic agents has been described, but there is insufficient evidence for routine use. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – Serious adverse outcomes from WN virus infection are limited to patients who develop neuroinvasive disease. Older age is the most important predictor of risk, although increased severity of neuroinvasive disease may also be seen in immunocompromised patients. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention
         </strong>
         – Personal protection measures include the use of mosquito repellents; general programs to protect public health include mosquito control programs and blood donor screening. A human vaccine is not yet available. (See
         <a class="local">
          'Prevention'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Considerations during pregnancy
         </strong>
         – Although a causal relationship between WN virus and fetal abnormalities has
         <strong>
          not
         </strong>
         been proven, pregnant women should take precautions to protect themselves from bites from potentially infected mosquitoes (eg, avoid being outdoors at dawn and dusk, wear protective clothing, use insect repellants containing DEET). If WN virus infection is diagnosed in pregnancy, care is supportive. (See
         <a class="local">
          'Special considerations during pregnancy'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Sejvar JJ, Haddad MB, Tierney BC, et al. Neurologic manifestations and outcome of West Nile virus infection. JAMA 2003; 290:511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gea-Banacloche J, Johnson RT, Bagic A, et al. West Nile virus: pathogenesis and therapeutic options. Ann Intern Med 2004; 140:545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morrey JD, Day CW, Julander JG, et al. Effect of interferon-alpha and interferon-inducers on West Nile virus in mouse and hamster animal models. Antivir Chem Chemother 2004; 15:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson JF, Rahal JJ. Efficacy of interferon alpha-2b and ribavirin against West Nile virus in vitro. Emerg Infect Dis 2002; 8:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sayao AL, Suchowersky O, Al-Khathaami A, et al. Calgary experience with West Nile virus neurological syndrome during the late summer of 2003. Can J Neurol Sci 2004; 31:194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalil AC, Devetten MP, Singh S, et al. Use of interferon-alpha in patients with West Nile encephalitis: report of 2 cases. Clin Infect Dis 2005; 40:764.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hrnicek MJ, Mailliard ME. Acute west nile virus in two patients receiving interferon and ribavirin for chronic hepatitis C. Am J Gastroenterol 2004; 99:957.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chowers MY, Lang R, Nassar F, et al. Clinical characteristics of the West Nile fever outbreak, Israel, 2000. Emerg Infect Dis 2001; 7:675.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Planitzer CB, Modrof J, Kreil TR. West Nile virus neutralization by US plasma-derived immunoglobulin products. J Infect Dis 2007; 196:435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agrawal AG, Petersen LR. Human immunoglobulin as a treatment for West Nile virus infection. J Infect Dis 2003; 188:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gnann JW Jr, Agrawal A, Hart J, et al. Lack of Efficacy of High-Titered Immunoglobulin in Patients with West Nile Virus Central Nervous System Disease. Emerg Infect Dis 2019; 25:2064.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pyrgos V, Younus F. High-dose steroids in the management of acute flaccid paralysis due to West Nile virus infection. Scand J Infect Dis 2004; 36:509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zaltzman R, Klein C, Gordon CR. Opsoclonus myoclonus ataxia associated with West Nile virus infection: A dramatic presentation with benign prognosis? J Neurol Sci 2017; 376:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karagianni P, Alexopoulos H, Sourdi A, et al. West Nile Virus infection triggering autoimmune encephalitis: Pathophysiological and therapeutic implications. Clin Immunol 2019; 207:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leis AA, Sinclair DJ. Lazarus Effect of High Dose Corticosteroids in a Patient With West Nile Virus Encephalitis: A Coincidence or a Clue? Front Med (Lausanne) 2019; 6:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murray KO, Baraniuk S, Resnick M, et al. Clinical investigation of hospitalized human cases of West Nile virus infection in Houston, Texas, 2002-2004. Vector Borne Zoonotic Dis 2008; 8:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rabel PO, Planitzer CB, Farcet MR, et al. Increasing West Nile virus antibody titres in central European plasma donors from 2006 to 2010. Euro Surveill 2011; 16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Srivastava R, Ramakrishna C, Cantin E. Anti-inflammatory activity of intravenous immunoglobulins protects against West Nile virus encephalitis. J Gen Virol 2015; 96:1347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rhee C, Eaton EF, Concepcion W, Blackburn BG. West Nile virus encephalitis acquired via liver transplantation and clinical response to intravenous immunoglobulin: case report and review of the literature. Transpl Infect Dis 2011; 13:312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yango AF, Fischbach BV, Levy M, et al. West Nile virus infection in kidney and pancreas transplant recipients in the Dallas-Fort Worth Metroplex during the 2012 Texas epidemic. Transplantation 2014; 97:953.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aziz F, Saddler C, Jorgenson M, et al. Epidemiology, management, and graft outcomes after West Nile virus encephalitis in kidney transplant recipients. Transpl Infect Dis 2020; 22:e13317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Popescu CP, Florescu SA, Hasbun R, et al. Prediction of unfavorable outcomes in West Nile virus neuroinvasive infection - Result of a multinational ID-IRI study. J Clin Virol 2020; 122:104213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petersen LR, Marfin AA. West Nile virus: a primer for the clinician. Ann Intern Med 2002; 137:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Leary DR, Marfin AA, Montgomery SP, et al. The epidemic of West Nile virus in the United States, 2002. Vector Borne Zoonotic Dis 2004; 4:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koch M, Pozsgai É, Soós V, et al. Identifying risks for severity of neurological symptoms in Hungarian West Nile virus patients. BMC Infect Dis 2021; 21:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sejvar JJ, Bode AV, Marfin AA, et al. West Nile virus-associated flaccid paralysis. Emerg Infect Dis 2005; 11:1021.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soto RA, McDonald E, Annambhotla P, et al. West Nile Virus Transmission by Solid Organ Transplantation and Considerations for Organ Donor Screening Practices, United States. Emerg Infect Dis 2022; 28:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDonald E, Mathis S, Martin SW, et al. Surveillance for West Nile virus disease - United States, 2009-2018. Am J Transplant 2021; 21:1959.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murray KO, Garcia MN, Rahbar MH, et al. Survival analysis, long-term outcomes, and percentage of recovery up to 8 years post-infection among the Houston West Nile virus cohort. PLoS One 2014; 9:e102953.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sejvar JJ. The long-term outcomes of human West Nile virus infection. Clin Infect Dis 2007; 44:1617.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carson PJ, Konewko P, Wold KS, et al. Long-term clinical and neuropsychological outcomes of West Nile virus infection. Clin Infect Dis 2006; 43:723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loeb M, Hanna S, Nicolle L, et al. Prognosis after West Nile virus infection. Ann Intern Med 2008; 149:232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murray KO, Garcia MN, Rahbar MH, et al. Survival analysis, long-term outcomes, and percentage of recovery up to 8 years post-infection among the Houston West Nile virus cohort. PLoS One 2014; 9:e102953.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yeung MW, Tomlinson G, Loeb M, Sander B. Health-related quality of life in persons with West Nile virus infection: a longitudinal cohort study. Health Qual Life Outcomes 2017; 15:210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burton JM, Kern RZ, Halliday W, et al. Neurological manifestations of West Nile virus infection. Can J Neurol Sci 2004; 31:185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marciniak C, Sorosky S, Hynes C. Acute flaccid paralysis associated with West Nile virus: motor and functional improvement in 4 patients. Arch Phys Med Rehabil 2004; 85:1933.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sejvar JJ, Bode AV, Marfin AA, et al. West Nile Virus-associated flaccid paralysis outcome. Emerg Infect Dis 2006; 12:514.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Betensley AD, Jaffery SH, Collins H, et al. Bilateral diaphragmatic paralysis and related respiratory complications in a patient with West Nile virus infection. Thorax 2004; 59:268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cao NJ, Ranganathan C, Kupsky WJ, Li J. Recovery and prognosticators of paralysis in West Nile virus infection. J Neurol Sci 2005; 236:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hadler JL, Patel D, Bradley K, et al. National capacity for surveillance, prevention, and control of West Nile virus and other arbovirus infections--United States, 2004 and 2012. MMWR Morb Mortal Wkly Rep 2014; 63:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gujral IB, Zielinski-Gutierrez EC, LeBailly A, Nasci R. Behavioral risks for West Nile virus disease, northern Colorado, 2003. Emerg Infect Dis 2007; 13:419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Han LL, Popovici F, Alexander JP Jr, et al. Risk factors for West Nile virus infection and meningoencephalitis, Romania, 1996. J Infect Dis 1999; 179:230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nasci RS, Mutebi JP. Reducing West Nile Virus Risk Through Vector Management. J Med Entomol 2019; 56:1516.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carney RM, Husted S, Jean C, et al. Efficacy of aerial spraying of mosquito adulticide in reducing incidence of West Nile Virus, California, 2005. Emerg Infect Dis 2008; 14:747.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lothrop HD, Lothrop BB, Gomsi DE, Reisen WK. Intensive early season adulticide applications decrease arbovirus transmission throughout the Coachella Valley, Riverside County, California. Vector Borne Zoonotic Dis 2008; 8:475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruktanonchai DJ, Stonecipher S, Lindsey N, et al. Effect of aerial insecticide spraying on West Nile virus disease--north-central Texas, 2012. Am J Trop Med Hyg 2014; 91:240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duprey Z, Rivers S, Luber G, et al. Community aerial mosquito control and naled exposure. J Am Mosq Control Assoc 2008; 24:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Human exposure to mosquito-control pesticides--Mississippi, North Carolina, and Virginia, 2002 and 2003. MMWR Morb Mortal Wkly Rep 2005; 54:529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Surveillance for acute insecticide-related illness associated with mosquito-control efforts--nine states, 1999-2002. MMWR Morb Mortal Wkly Rep 2003; 52:629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chung WM, Buseman CM, Joyner SN, et al. The 2012 West Nile encephalitis epidemic in Dallas, Texas. JAMA 2013; 310:297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petersen LR. Epidemiology of West Nile Virus in the United States: Implications for Arbovirology and Public Health. J Med Entomol 2019; 56:1456.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaiser JA, Barrett ADT. Twenty Years of Progress Toward West Nile Virus Vaccine Development. Viruses 2019; 11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin JE, Pierson TC, Hubka S, et al. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis 2007; 196:1732.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ledgerwood JE, Pierson TC, Hubka SA, et al. A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. J Infect Dis 2011; 203:1396.
          </a>
         </li>
         <li class="breakAll">
          Coller IB, Pai V, Weeks-Levy CL, Ogata SA. Recombinant subunit West Nile virus vaccine for protection of human subjects. US Patent 0165349 A1. 15 June 2017.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pierce KK, Whitehead SS, Kirkpatrick BD, et al. A Live Attenuated Chimeric West Nile Virus Vaccine, rWN/DEN4Δ30, Is Well Tolerated and Immunogenic in Flavivirus-Naive Older Adult Volunteers. J Infect Dis 2017; 215:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Durbin AP, Karron RA, Sun W, et al. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. Am J Trop Med Hyg 2001; 65:405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woods CW, Sanchez AM, Swamy GK, et al. An observer blinded, randomized, placebo-controlled, phase I dose escalation trial to evaluate the safety and immunogenicity of an inactivated West Nile virus Vaccine, HydroVax-001, in healthy adults. Vaccine 2019; 37:4222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barrett PN, Terpening SJ, Snow D, et al. Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases. Expert Rev Vaccines 2017; 16:883.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monath TP, Liu J, Kanesa-Thasan N, et al. A live, attenuated recombinant West Nile virus vaccine. Proc Natl Acad Sci U S A 2006; 103:6694.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biedenbender R, Bevilacqua J, Gregg AM, et al. Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults. J Infect Dis 2011; 203:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dayan GH, Bevilacqua J, Coleman D, et al. Phase II, dose ranging study of the safety and immunogenicity of single dose West Nile vaccine in healthy adults ≥ 50 years of age. Vaccine 2012; 30:6656.
          </a>
         </li>
         <li class="breakAll">
          U.S. Centers for Disease Control. Interim Guidelines for the Evaluation of Infants Born to Mothers Infected With West Nile Virus During Pregnancy. www.cdc.gov/ncidod/dvbid/westnile/congenitalinterimguidelines.htm (Accessed on March 07, 2005).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Interim guidelines for the evaluation of infants born to mothers infected with West Nile virus during pregnancy. MMWR Morb Mortal Wkly Rep 2004; 53:154.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1282 Version 16.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12876094" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Neurologic manifestations and outcome of West Nile virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15068983" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : West Nile virus: pathogenesis and therapeutic options.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15185728" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Effect of interferon-alpha and interferon-inducers on West Nile virus in mouse and hamster animal models.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11749765" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Efficacy of interferon alpha-2b and ribavirin against West Nile virus in vitro.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15198443" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Calgary experience with West Nile virus neurological syndrome during the late summer of 2003.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15714427" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Use of interferon-alpha in patients with West Nile encephalitis: report of 2 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15128371" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Acute west nile virus in two patients receiving interferon and ribavirin for chronic hepatitis C.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11585531" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Clinical characteristics of the West Nile fever outbreak, Israel, 2000.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17597458" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : West Nile virus neutralization by US plasma-derived immunoglobulin products.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12825164" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Human immunoglobulin as a treatment for West Nile virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31625835" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Lack of Efficacy of High-Titered Immunoglobulin in Patients with West Nile Virus Central Nervous System Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15307586" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : High-dose steroids in the management of acute flaccid paralysis due to West Nile virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28431624" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Opsoclonus myoclonus ataxia associated with West Nile virus infection: A dramatic presentation with benign prognosis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31454696" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : West Nile Virus infection triggering autoimmune encephalitis: Pathophysiological and therapeutic implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31106205" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Lazarus Effect of High Dose Corticosteroids in a Patient With West Nile Virus Encephalitis: A Coincidence or a Clue?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18399781" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Clinical investigation of hospitalized human cases of West Nile virus infection in Houston, Texas, 2002-2004.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21435324" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Increasing West Nile virus antibody titres in central European plasma donors from 2006 to 2010.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25667322" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Anti-inflammatory activity of intravenous immunoglobulins protects against West Nile virus encephalitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21235711" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : West Nile virus encephalitis acquired via liver transplantation and clinical response to intravenous immunoglobulin: case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24827765" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : West Nile virus infection in kidney and pancreas transplant recipients in the Dallas-Fort Worth Metroplex during the 2012 Texas epidemic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32386074" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Epidemiology, management, and graft outcomes after West Nile virus encephalitis in kidney transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31778945" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Prediction of unfavorable outcomes in West Nile virus neuroinvasive infection - Result of a multinational ID-IRI study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12160365" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : West Nile virus: a primer for the clinician.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15018774" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : The epidemic of West Nile virus in the United States, 2002.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33441090" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Identifying risks for severity of neurological symptoms in Hungarian West Nile virus patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16022775" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : West Nile virus-associated flaccid paralysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34843660" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : West Nile Virus Transmission by Solid Organ Transplantation and Considerations for Organ Donor Screening Practices, United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33939278" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Surveillance for West Nile virus disease - United States, 2009-2018.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25054656" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Survival analysis, long-term outcomes, and percentage of recovery up to 8 years post-infection among the Houston West Nile virus cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17516407" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : The long-term outcomes of human West Nile virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16912946" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Long-term clinical and neuropsychological outcomes of West Nile virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18711153" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Prognosis after West Nile virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25054656" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Survival analysis, long-term outcomes, and percentage of recovery up to 8 years post-infection among the Houston West Nile virus cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29061146" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Health-related quality of life in persons with West Nile virus infection: a longitudinal cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15198442" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Neurological manifestations of West Nile virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15605329" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Acute flaccid paralysis associated with West Nile virus: motor and functional improvement in 4 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16704798" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : West Nile Virus-associated flaccid paralysis outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14985569" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Bilateral diaphragmatic paralysis and related respiratory complications in a patient with West Nile virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15967468" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Recovery and prognosticators of paralysis in West Nile virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24699764" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : National capacity for surveillance, prevention, and control of West Nile virus and other arbovirus infections--United States, 2004 and 2012.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17552095" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Behavioral risks for West Nile virus disease, northern Colorado, 2003.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9841844" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Risk factors for West Nile virus infection and meningoencephalitis, Romania, 1996.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31549724" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Reducing West Nile Virus Risk Through Vector Management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18439356" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Efficacy of aerial spraying of mosquito adulticide in reducing incidence of West Nile Virus, California, 2005.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18494603" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Intensive early season adulticide applications decrease arbovirus transmission throughout the Coachella Valley, Riverside County, California.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24778196" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Effect of aerial insecticide spraying on West Nile virus disease--north-central Texas, 2012.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18437813" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Community aerial mosquito control and naled exposure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15931155" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Human exposure to mosquito-control pesticides--Mississippi, North Carolina, and Virginia, 2002 and 2003.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12855943" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Surveillance for acute insecticide-related illness associated with mosquito-control efforts--nine states, 1999-2002.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23860988" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : The 2012 West Nile encephalitis epidemic in Dallas, Texas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31549728" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Epidemiology of West Nile Virus in the United States: Implications for Arbovirology and Public Health.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31491885" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Twenty Years of Progress Toward West Nile Virus Vaccine Development.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18190252" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21398392" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21398392" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28077583" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : A Live Attenuated Chimeric West Nile Virus Vaccine, rWN/DEN4Δ30, Is Well Tolerated and Immunogenic in Flavivirus-Naive Older Adult Volunteers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11716091" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30661836" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : An observer blinded, randomized, placebo-controlled, phase I dose escalation trial to evaluate the safety and immunogenicity of an inactivated West Nile virus Vaccine, HydroVax-001, in healthy adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28724343" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16617103" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : A live, attenuated recombinant West Nile virus vaccine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21148499" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22959989" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Phase II, dose ranging study of the safety and immunogenicity of single dose West Nile vaccine in healthy adults≥50 years of age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22959989" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Phase II, dose ranging study of the safety and immunogenicity of single dose West Nile vaccine in healthy adults≥50 years of age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14985654" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Interim guidelines for the evaluation of infants born to mothers infected with West Nile virus during pregnancy.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
